Biogen sees negative Q2 impact from IPR&D, milestone expenses

4 hours ago 2

• Earnings News
• Healthcare

filo

• Biogen said it will incur a $46M charge in its Q2 results leading to a ($0.26) impact in its GAAP and non-GAAP EPS due to acquired in-process research and development (IPR&D), upfront, and milestone expenses.
• The biotech said it began

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Biogen sees negative Q2 impact from IPR&D, milestone expenses